Replies to post #55133 on Avid Bioservices Inc (CDMO)

[Bungler]

entdoc, "HDTRA1-08-C-0003" is the original DTRA contract with Peregrine. It is not Bavi under another name. It IS Bavi under the DTRA Peregrine contract. Utah State is supporting Peregrine. Please remember that Bavi is a proprietary technology covered by multiple US and worldwide patents. Thus, DTRA would not have the right to go other research facilities regarding Bavi without the consent and permission of Peregrine. The following is from a spreadsheet on dtra.mil:

Contract Number
HDTRA1-08-C-0003-P00006

Vendor Name
PEREGRINE PHARMACEUTICALS, INC.

Award Total Cost
$44,403,716

Obligated Amount
$2,956,209

Award Released Date
03/25/10


Also note the following, what can "One-Size-Fits-All" be referring to:

Transformational Medical Technologies Initiative
Developing a “One-Size-Fits-All” Defense Against Biological Threats

How do you deter and protect against bioengineered threats that may be mounted in the future by small groups rather than nation states?

In the decades before the end of the Cold War, the threat from biological weapons originated from state-run programs, which had the resources and expertise to develop horrific weapons. Fortunately, through significant investments and international cooperation, the threat posed by biological weapons programs has been significantly reduced.

However, as time went on, the expertise and resources needed to develop biological weapons have inadvertently became more widespread. Now, anyone – including rogue states and terrorist groups—with the right know-how can develop these dangerous weapons. This is an especially challenging problem facing not only the American warfighter, but also the entire United States and the world.

DTRA’s response to this challenge is the Transformational Medical Technologies Initiative (TMTI).

Through TMTI, DTRA is leading the way to find ways to protect the American warfighter from conventional and genetically engineered biological threats by accelerating the research and development of medical countermeasures.

The program leverages capabilities found in the higher education and research communities as well as through the private sector by offering funding for research into medical science and technology initiatives using cutting-edge technologies and innovative management approaches. Since it’s beginnings in Fiscal Year 2006, program awards were given to industry, academia and the government for potential products, platforms and enabling technologies.

Speed is the key. TMTI allows for the rapid response to new biological threats by combining all aspects of response, from identification of the threat to the manufacturing of those new countermeasures. Faster the response equals more lives saved.

TMTI also aims to develop countermeasures that will address a broad spectrum of biological threats, whether they are traditional or bioengineered. This “One-Size-Fits-All” approach is intended to better prepare our nations men and women in uniform on the front lines, ensuring they are ready for any threat they may face.